Fucoidan Alleviates Renal Fibrosis in Diabetic Kidney Disease via Inhibition of NLRP3 Inflammasome-Mediated Podocyte Pyroptosis

Background: Fucoidan (FPS) has been widely used to treat renal fibrosis (RF) in patients with diabetic kidney disease (DKD); however, the precise therapeutic mechanisms remain unclear. Recently, research focusing on inflammation-derived podocyte pyroptosis in DKD has attracted increasing attention....

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Mei-Zi Wang, Jie Wang, Dong-Wei Cao, Yue Tu, Bu-Hui Liu, Can-Can Yuan, Huan Li, Qi-Jun Fang, Jia-Xin Chen, Yan Fu, Bing-Ying Wan, Zi-Yue Wan, Yi-Gang Wan, Guo-Wen Wu
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2022-03-01
Saila:	Frontiers in Pharmacology
Gaiak:	fucoidan diabetic kidney disease renal fibrosis podocyte pyroptosis NLRP3 inflammasome
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fphar.2022.790937/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!